ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company�s principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company�s lead product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of atrial fibrillation (AF) in patients with heart failure and/or left ventricular dysfunction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The active pharmaceutical ingredient (API) in Gencaro, bucindolol hydrochloride, has been tested clinically in approximately 4,500 patients. Gencaro was the subject of a Phase III HF mortality trial of over 2,700 patients, mostly in the United States.